forecast glp-1 prescriptions growth 2025 semaglutide tirzepatide Drugs Market Size to Hit USD 132.79 Bn by 2035 Two Years After Stopping GLP-1s,

Combining glucagon-receptor agonism with GLP-1/GIP agonism would seem to work against itself

The key milestones include: exenatide approval (2005), liraglutide approval (2010), semaglutide injection approval (2017), oral semaglutide with SNAC approval (2019), orforglipron cryo-EM structure published (2020), orforglipron Phase 2 results in NEJM (2023), orforglipron Phase 3 ATTAIN-1 results in NEJM (2025), and FDA regulatory submission (2025)

Hair typically recovers fully once weight stabilizes and nutrition normalizes

10.1007/BF00606554 Eur J Clin Pharmacol

Journal of the American College of Nutrition, 26(6), 536-541